🇺🇸 tenofovir, lamivudine, efavirenz in United States

17 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Foetal Exposure During Pregnancy — 3 reports (17.65%)
  2. Abdominal Pain — 2 reports (11.76%)
  3. Exposure During Pregnancy — 2 reports (11.76%)
  4. Hypertension — 2 reports (11.76%)
  5. Stillbirth — 2 reports (11.76%)
  6. Vomiting — 2 reports (11.76%)
  7. Acute Kidney Injury — 1 report (5.88%)
  8. Alanine Aminotransferase Increased — 1 report (5.88%)
  9. Anoxia — 1 report (5.88%)
  10. Aspartate Aminotransferase Increased — 1 report (5.88%)

Source database →

Other Infectious Disease / Virology approved in United States

Frequently asked questions

Is tenofovir, lamivudine, efavirenz approved in United States?

tenofovir, lamivudine, efavirenz does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for tenofovir, lamivudine, efavirenz in United States?

Bamrasnaradura Infectious Diseases Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.